AstraZeneca, an Anglo-Swedish company, recently completed similar agreements with Britain, the United States the Coalition for Epidemic Preparedness Innovations, and Gavi, the Vaccine Alliance for 700 million doses.
AstraZeneca Plc has signed a contract with four European governments to supply the region with its potential vaccine against the coronavirus, the British drugmaker's latest deal to pledge its drug to help combat the pandemic.
The contract is for up to 400 million doses of the vaccine, developed by the University of Oxford, the company said on Saturday, adding that it was looking to expand manufacturing of the vaccine, which it said it would provide for no profit during the pandemic.
Deliveries will start by the end of 2020.
Mounting global demand
The deal is the first contract signed by Europe's Inclusive Vaccines Alliance (IVA), a group formed by France, Germany, Italy and the Netherlands to secure vaccine doses for all member states as soon as possible.
"This will ensure that hundreds of millions of people in Europe will have access to this vaccine, of course, if it works and we will know that by the end of summer," the company's chief executive, Pascal Soriot told journalists. He said he has "good hope" that it will work, based on initial data.
The alliance "will work together with the European Commission and other countries in Europe to ensure everybody across Europe is supplied with the vaccine," he said.
"We have a very self-sufficient supply chain for Europe" with manufacturers lined up in the Netherlands, Germany, Italy and Italy, among others, he said.
The vaccines are for all EU member states. The four nations that agreed the deal will pay for the total amount, which has not been disclosed, and the scheme allows other countries to join it under the same conditions, a source from the Italian health ministry said.
Phase for human tests
The British Medicines and Healthcare products Regulatory Agency (MHRA) has approved the start of Phase III trials of the vaccine after studies showed sufficient efficacy and safety, Soriot said.
At a meeting of EU Health Ministers on Friday, IVA agreed to merge its activities with those of the EU Commission, Germany's Health Ministry said.
The deal is the latest by AstraZeneca to promise to supply its vaccine to governments who have scrambled to agree on advance purchases of promising coronavirus immunisation treatments.
It has agreed manufacturing deals globally to meet its target of producing 2 billion doses of the vaccine, including with two Bill Gates-backed ventures and a $1.2 billion agreement with the US government.
The deal will add a further 100 million doses to the 2 billion already committed by the group, AstraZeneca said.
There are no approved vaccines or treatments for Covid-19, the highly contagious respiratory illness caused by the novel coronavirus.
"Many countries in the world have already secured vaccines, Europe has not yet. The rapid coordinated action of a group of member states will create added value for all EU citizens in this crisis," Italian Health Minister Roberto Speranza said.
Race for vaccine
A license also has been agreed with the Serum Institute of India for another 1 billion doses.
AstraZeneca is also in talks with Japan, Russia, Brazil and China about supply deals for its potential coronavirus vaccine, its chief said.
Read more: Japan’s AnGes speeds towards 2021 rollout in coronavirus ‘vaccine war’
Other companies, including Moderna and Sanofi, are racing to develop and produce a vaccine against the new coronavirus, a step experts say will be crucial to easing restrictions on public life and preventing additional waves of infections.
Read more: Novavax begins human trials with potential Covid-19 vaccine in Australia